PHA Sacubitril

Published oct 29, 2021 sacubitril (entresta)inhibits trpm7 my personal target of interest.

-essential papers-

C8565918 2021. Focus on pharmacogenomics phytonutrient-drug interactions and COVID-19 vaccines: Perspectives on ADRs ADEs and SEDs.
C8444447 2021. Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.
C8317454 2021. Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2.
C7890335 2021. The spectrum of COVID-19 in complex adult congenital heart disease: A case series.
C8326513 2021. Receptors
C8091429 2021. PREDICTORS OF LIKELIHOOD OF TAKING SACUBITRIL-VALSARTAN AND A HYPOTHETICAL MEDICATION FOR COVID-19.
32921718 2020. How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.
31399990 2019. Antifibrotic Roles of RAAS Blockers: Update.
32502882 2020. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
33827074 2021. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
32639866 2020. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
32370986 2020. Renin-angiotensin-aldosterone system and COVID-19 infection.
34066998 2021. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics.
34134920 2021. Vasoactive Peptides: Their Role in COVID-19 Pathogenesis and Potential Use as Biomarkers and Therapeutic Targets.
32470547 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.
34715788 2021. Cardiogenic shock complicating multisystem inflammatory syndrome following COVID-19 infection: a case report.
33795925 2020. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.
32998363 2020. Angiotensin Inhibition, TGF-beta and EMT in Cancer.
32671601 2021. Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
33926209 2021. CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia.
32537662 2020. Impaired cardiac function is associated with mortality in patients with acute COVID-19 infection.
34055238 2021. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning.
33631357 2021. RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.
33005549 2020. COVID-19 Presenting as Major Thromboembolic Events: Virchow's Triad Revisited and Clinical Considerations of Therapeutic Anticoagulation.
33200501 2021. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission.
32420637 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.
33084001 2020. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
34754175 2021. What will be the role of molnupiravir in the treatment of COVID-19 infection?
34792677 2021. Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.
32955172 2020. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
33498096 2021. Worsening of heart failure by coronavirus disease 2019 is associated with high mortality.
33026699 2020. Being responsible for someone else: a shared duty for parents and heart failure specialists during the COVID-19 pandemic.
34031865 2021. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.
33659979 2021. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
32498078 2020. Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs.
32369103 2020. Sacubitril/valsartan in COVID-19 patients: the need for trials.
32282032 2020. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
32859477 2020. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study.
32926917 2020. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.
33011243 2020. New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.
33628162 2021. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.
34195234 2021. Myocardial Work Efficiency, A Novel Measure of Myocardial Dysfunction, Is Reduced in COVID-19 Patients and Associated With In-Hospital Mortality.
34778271 2021. Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel.
34603042 2021. Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway.
34539406 2021. Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/beta-Catenin Signaling Pathway.
34135764 2021. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-beta1/Smads Pathway.
33519461 2020. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.
32564908 2020. COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?
33688410 2020. COVID-19 and Heart Failure: The Big Challenge.
34739696 2021. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
32405088 2020. Cardiological society of India position statement on COVID-19 and heart failure.
33932192 2021. Brief review of the mRNA vaccines COVID-19.
33221168 2021. Potential role of interferons in treating COVID-19 patients.
33083516 2020. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19.
32875060 2020. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis.
32724831 2020. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management.
33145103 2020. Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.
33809971 2021. Renin-Angiotensin-Aldosterone System: Friend or Foe-The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions.
33203141 2020. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
33888248 2021. Another Nudge to Overcome the Treatment-Risk Paradox in Blood Pressure Management.
29042424 2017. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
32597315 2021. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
32694923 2020. Blood Targets of Adjuvant Drugs Against COVID19.
32282502 2020. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19).
32301766 2020. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
32937008 2020. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.
33490288 2021. The Cytokine Profiles and Immune Response Are Increased in COVID-19 Patients with Type 2 Diabetes Mellitus.
34429797 2021. COVID-19 Pneumonia Precipitating Acute Anterior Wall Myocardial Infarction With Large Left Ventricular Apical Thrombus.
33384064 2021. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19.
32265149 2020. End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV.
32493638 2020. Considerations for Heart Failure Care During the COVID-19 Pandemic.
33464336 2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
32558877 2020. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
33342753 2021. Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis.
33422263 2021. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
33607159 2021. COVID-19, cytokines, inflammation, and spices: How are they related?
32991879 2020. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.
32471831 2020. Reply to Siniorakis et al., "COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure".
32444383 2020. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
33804308 2021. Fibrosis after Myocardial Infarction: An Overview on Cellular Processes, Molecular Pathways, Clinical Evaluation and Prognostic Value.
33655986 2021. The semantic of a pandemic: Are cardiovascular patients dying "with" or "from" COVID-19? Reflections from a case report.
31567942 2019. Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction.
32587982 2020. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.
33806624 2021. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.
33837899 2021. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.
32356628 2020. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
32356627 2020. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
34151392 2021. The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.
32893306 2020. COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?
32596035 2020. LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-kappaB mediated inflammation and glomerulosclerosis in rats.
33275999 2021. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor.
33687143 2021. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?
33347477 2020. Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.
33006999 2020. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm.
33203679 2020. Targeting the renin-angiotensin signaling pathway in COVID-19: Unanswered questions, opportunities, and challenges.
33550151 2021. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
32999856 2020. Clinical deterioration during neutropenia recovery after G-CSF therapy in patient with COVID-19.
32905015 2020. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
33219294 2020. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
34035891 2021. Renin-angiotensin-aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis.
32553503 2020. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
34696334 2021. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.
33265982 2020. Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.
33877436 2021. Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.
33779831 2021. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.
32719054 2020. Sacubitril, valsartan and SARS-CoV-2.
26057694 2015. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
34075552 2021. Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
31790054 2020. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
27653223 2016. Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer?
33786624 2021. Sacubitril/valsartan inhibits oxLDLinduced MALAT1 expression, inflammation and apoptosis by suppressing the TLR4/NFkappaB signaling pathway in HUVECs.

further papers from pmc

29939681 2021. Sacubitril/Valsartan
33839697 2021. LCZ696 ameliorates lipopolysaccharide-induced endothelial injury.
32463726 2020. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension.
29312499 2017. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.
33074771 2021. Renal Denervation to Treat Heart Failure.
33437485 2020. Management of Cardiac Sarcoidosis in 2020.
31108352 2019. The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet.
25778676 2015. Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases.
30225980 2019. Three-dimensional electron microscopy techniques for unravelling mitochondrial dysfunction in heart failure and identification of new pharmacological targets.
26989394 2016. Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome.
30909895 2019. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
33708498 2021. Pathophysiology of heart failure.
32444995 2020. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
34359886 2021. Cardiac Fibrosis and Fibroblasts.
32059634 2020. Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
31707802 2019. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
33983837 2021. Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure.
32648130 2020. Heart Failure with Preserved Ejection Fraction-a Concise Review.
30543176 2019. Shock - Classification and Pathophysiological Principles of Therapeutics.
32103902 2020. Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-beta1 Signaling in Kidney.
32310257 2020. GDF15: A Hormone Conveying Somatic Distress to the Brain.
33295126 2021. Time-sensitive approach in the management of acute heart failure.
30837806 2019. Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments.
29249907 2017. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan.
30592365 2019. Adrenomedullin in heart failure: pathophysiology and therapeutic application.
31262190 2019. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
31906742 2020. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.
34447792 2021. Hypoxia Inducible Factors as Central Players in the Pathogenesis and Pathophysiology of Cardiovascular Diseases.
34409075 2021. Heart Failure Syndrome With Preserved Ejection Fraction Is a Metabolic Cluster of Non-resolving Inflammation in Obesity.
33969025 2021. Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction.
34490241 2021. Oxidative Stress-Induced Ferroptosis in Cardiovascular Diseases and Epigenetic Mechanisms.
33859992 2021. Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease.
34135773 2021. Protective Renal Effects of Atrial Natriuretic Peptide: Where Are We Now?
31749710 2019. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.
30534079 2018. Mechanisms and Modulation of Oxidative/Nitrative Stress in Type 4 Cardio-Renal Syndrome and Renal Sarcopenia.
30565021 2019. Practical guidance on the use of sacubitril/valsartan for heart failure.
33957252 2021. Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats.
27032551 2016. Rescue of Heart Failure by Mitochondrial Recovery.
29050562 2017. Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
33615821 2021. Revisiting and Implementing the Weber and Ventilatory Functional Classifications in Heart Failure by Cardiopulmonary Imaging Phenotyping.
32791029 2020. Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.
29325796 2018. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
34063477 2021. Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?
32870495 2021. Renal dysfunction in cardiovascular diseases and its consequences.
31924408 2020. The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats.
31412886 2019. Meeting abstracts from the 9th International Conference on cGMP: Generators, Effectors and Therapeutic Implications.
28944310 2017. Metabolic Origins of Heart Failure.
30235455 2018. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome.
33777494 2021. Anemia of cardiorenal syndrome.
30597709 2019. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.
34296299 2021. Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3induced pyroptosis via the TAK1/JNK signaling pathway.
32139695 2020. Acute heart failure.
31073128 2019. Dilated cardiomyopathy.
34759348 2021. Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation.
31673162 2020. Kidney disease trials for the 21st century: innovations in design and conduct.
32739920 2020. Proenkephalin: A New Biomarker for Glomerular Filtration Rate and Acute Kidney Injury.
33922366 2021. Chagas Cardiomyopathy: From Romana Sign to Heart Failure and Sudden Cardiac Death.
32747644 2020. A novel protective role of sacubitril/valsartan in cyclophosphamide induced lung injury in rats: impact of miRNA-150-3p on NF-kappaB/MAPK signaling trajectories.
31019233 2019. Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
34079271 2021. Epigenetic Therapies for Heart Failure: Current Insights and Future Potential.
32879702 2020. Sympathetic nervous system activation and heart failure: Current state of evidence and the pathophysiology in the light of novel biomarkers.
33870733 2021. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.
27129187 2016. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.
32488503 2020. Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
34216577 2021. Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application.
33581182 2021. Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction.
33310048 2021. Sacubitril/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism.
23023670 2012. Trial watch: dual-acting combination meets heart failure end point.
20431556 2010. Trial watch: dual inhibition shows promise in hypertension.
33541194 2021. Inhibition of neprilysin with sacubitril without RAS blockage aggravates renal disease in Dahl SS rats.